Edition:
United Kingdom

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

23.40USD
18 May 2018
Change (% chg)

$0.45 (+1.96%)
Prev Close
$22.95
Open
$23.00
Day's High
$23.45
Day's Low
$22.95
Volume
128,080
Avg. Vol
210,409
52-wk High
$23.45
52-wk Low
$11.85

Select another date:

Tue, May 8 2018

BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.63

* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18

* MOMENTA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL AND LAUNCH OF GLATOPA® (GLATIRAMER ACETATE INJECTION) 40 MG/ML

BRIEF-Momenta Pharmaceuticals Announces Positive Outcome For Contracted Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME FOR CONTRACTED GLATOPA (GLATIRAMER ACETATE INJECTION) FILL/FINISH MANUFACTURER Source text for Eikon: Further company coverage:

BRIEF-Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However

* MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING Source text:(http://bit.ly/2CTkx5R) Further company coverage:

BRIEF-Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof Of Mechanism For M281

* MOMENTA PHARMACEUTICALS REPORTS POSITIVE TOP-LINE PHASE 1 DATA SHOWING PROOF OF MECHANISM FOR M281, AN ANTI-FCRN MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Jan 3 Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

BRIEF-Momenta And Mylan Announce Development Strategy For Proposed Biosimilar To Eylea

* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)

Select another date: